New Targets for Antivirals: The Ribosomal A-Site and the Factors That Interact with It  by Goss Kinzy, Terri et al.
Virology 300, 60–70 (2002)New Targets for Antivirals: The Ribosomal A-Site and the Factors That Interact with It
Terri Goss Kinzy,*,¶ Jason W. Harger,*,†,§ Anne Carr-Schmid,*,† Jane Kwon,* Mythili Shastry,‡
Michael Justice,‡ and Jonathan D. Dinman§,1
*Department of Molecular Genetics and Microbiology and †The Graduate Program in Molecular Biosciences at UMDNJ/Rutgers Universities,
UMDNJ Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854; ‡The Department of Human and Animal Infectious
Disease Research, Merck Research Laboratories, Rahway, New Jersey 08065; §The Department of Cell Biology and Molecular Genetics,
University of Maryland, College Park, Maryland 20742; and ¶The Cancer Institute of New Jersey, Piscataway, New Jersey 08854
Received April 17, 2002; returned to author for revision May 8, 2002; accepted May 15, 2002
Many viruses use programmed 1 ribosomal frameshifting to ensure the correct ratio of viral structural to enzymatic
proteins. Alteration of frameshift efficiencies changes these ratios, in turn inhibiting viral particle assembly and virus
propagation. Previous studies determined that anisomycin, a peptidyl transferase inhibitor, specifically inhibited 1 frame-
shifting and the ability of yeast cells to propagate the L-A and M1 dsRNA viruses (J. D. Dinman, M. J. Ruiz-Echevarria, K.
Czaplinski, and S. W. Peltz, 1997, Proc. Natl. Acad. Sci. USA 94, 6606–6611). Here we show that preussin, a pyrollidine that
is structurally similar to anisomycin (R. E. Schwartz, J. Liesch, O. Hensens, L. Zitano, S. Honeycutt, G. Garrity, R. A. Fromtling,
J. Onishi, and R. Monaghan, 1988. J. Antibiot. (Tokyo) 41, 1774-1779), also inhibits 1 programmed ribosomal frameshifting
and virus propagation by acting at the same site or through the same mechanism as anisomycin. Since anisomycin is known
to assert its effect at the ribosomal A-site, we undertook a pharmacogenetic analysis of mutants of trans-acting eukaryotic
elongation factors (eEFs) that function at this region of the ribosome. Among mutants of eEF1A, a correlation is observed
between resistance/susceptibility profiles to preussin and anisomycin, and these in turn correlate with programmed 1
ribosomal frameshifting efficiencies and killer virus phenotypes. Among mutants of eEF2, the extent of resistance to preussin
correlates with resistance to sordarin, an eEF2 inhibitor. These results suggest that structural features associated with the
ribosomal A-site and with the trans-acting factors that interact with it may present a new set of molecular targets for theINTRODUCTION
Classically, anti-retroviral strategies have targeted vi-
rus-encoded proteins, e.g., reverse transcriptase and
protease, on the theory that compromising these virus-
specific functions will have minimal impact on the health
of the host. Unfortunately, since viral populations evolve
on time scales of weeks to months, drug resistance
emerges rapidly. Thus, though the treatment of HIV-AIDS
has been revolutionized through the development of
highly active anti-retroviral therapy (HAART), multiple
drug resistance has emerged threatening to undo the
substantial advances that have been made (UNAIDS/
WHO Global AIDS Statistics, 2001). An alternative strat-
egy would involve targeting a host-encoded function that,
if slightly altered, would have minimal effect on the host
but be deleterious to the virus. As we have previously
discussed, programmed1 ribosomal frameshifting pre-
sents a promising candidate (Dinman et al., 1998).
Many classes of RNA viruses utilize programmed ri-
bosomal frameshifting (PRF) as a means to express© 2002 Elsevier Science (USA)
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60multiple protein products while condensing genome size
(reviewed in Brierley, 1995; Farabaugh, 1996). The effi-
ciency of PRF helps to determine the ratio of viral struc-
tural to enzymatic proteins available for the viral particle
morphogenic program, and even slight alterations in
frameshift frequencies can severely inhibit virus propa-
gation (reviewed in Dinman et al., 1998). The identifica-
tion of compounds that affect this process can be aided
by integrating the models describing PRF into the context
of the host-cellular process in which they occur, i.e., the
translation elongation cycle. A summary of recent re-
search shows that programmed 1 ribosomal frame-
shifting must occur during the translation elongation cy-
cle after delivery of cognate aminoacyl-tRNA (aa-tRNA) to
the ribosome and prior to the peptidyl transfer step
(Dinman and Kinzy, 1997; Dinman et al., 1997; Tumer et
al., 1998; Meskauskas and Dinman, 2001; Harger et al.,
2001). This “Integrated Model” of programmed ribosomal
frameshifting previously led us to demonstrate that two
peptidyl transferase inhibitors, anisomycin and sparso-
mycin, have antiviral properties (Dinman et al., 1997).
These drugs inhibit peptidyl transfer by distinct mecha-rational design of antiviral compounds. © 2002 Elsevier Scien
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anisomycin inhibits peptidyl transfer by blocking the “ac-
commodation” step of translation, i.e., the active insertion
of the 3 end of the aa-tRNA into the A-site of the ribo-
somal peptidyl transferase center by eukaryotic elonga-
tion factor 1A (eEF1A). In contrast, sparsomycin inhibits
peptidyl transfer both by increasing the affinity of the
ribosomal P-site for the 3 end of the peptidyl-tRNA and
by altering its alignment relative to the peptidyl trans-
ferase active center. Here, we report that preussin, a
natural product isolated from Aspergillus ochraceus that
shares structural features with anisomycin (Schwartz et
al., 1988), has similar antiviral properties.
Building on the knowledge that anisomycin and preus-
sin inhibit a ribosomal A-site-associated function, we
also conducted a screen of known mutants of the trans-
acting factors that interact with the A-site in an effort to
identify potential new targets for antiviral compounds.
eEF1A delivers aminoacyl-tRNAs (aa-tRNA) to the ribo-
somal A-site, and eukaryotic elongation factor 2 (eEF2)
translocates the newly formed peptidyl-tRNA to the P-site
(reviewed in Merrick and Nyborg, 2000). The prokaryotic
homologs of these factors, EF-Tu, bound to aa-tRNA and
EF-G, respectively, share a striking amount of overall
structural similarity (Nissen et al., 2000; Czworkowski et
al., 1994; al Karadaghi et al., 1996), and the high degree
of structural conservation between EF-Tu and eEF1A
suggests a similar relationship between eukaryotic elon-
gation factors (Andersen et al., 2000). Molecular mimicry
models of proteins resembling tRNA structures (re-
viewed in Nissen et al., 2000) shared structural charac-
teristics of A-site factors (see above), and overlapping
binding sites on the ribosome (reviewed in Noller, 1997)
indicate a rich array of targets for addressing A-site
functions in viral maintenance. The emerging picture is
that alteration of the accommodation step of translation
is a mechanism that can severely impact on 1 PRF
efficiency and virus propagation. Our finding that clusters
of mutants in both eEF1A and eEF2 are resistant to both
preussin and anisomycin suggest a new set of targets for
the rational design of new antiviral agents.
RESULTS AND DISCUSSION
Preussin specifically inhibits programmed 1
ribosomal frameshifting and cures yeast cells of the
killer virus by the same mechanism as anisomycin
In a previous study we showed that agents with the
property of being able to inhibit the peptidyl transferase
reaction specifically altered programmed 1 ribosomal
frameshifting and had antiviral activities (Dinman et al.,
1997). These studies also demonstrated that alteration of
PRF was specific to these two agents and not a general
property of translational inhibitors per se. One of the
peptidyl transferase inhibitors, anisomycin, specifically
affects the accommodation step of the translation cycle
by inhibiting binding of the aa-tRNA 3 stem to the ac-
ceptor site of the peptidyl transferase center (Grollman,
1967; Carrasco et al., 1973). This in turn results in inhi-
bition of the peptidyl transferase reaction. In searching
for other compounds with comparable properties, we
noted that the chemical structure of preussin is very
similar to anisomycin (Fig. 1) (Schwartz et al., 1988). The
yeast strain JD88 was chosen for use in studies to
examine the potential effects of this compound on 1
PRF and virus propagation because it is the same strain
that was used in the anisomycin studies, thus allowing
for direct comparison of these two drugs on PRF and
virus propagation. JD88 harbors the yeast “Killer” virus,
which provides a convenient marker for the effects of
mutants and drugs on 1 PRF and virus propagation
(reviewed in Dinman et al., 1988). The killer virus is
composed of the 4.6-kb dsRNA L-A virus (family Totiviri-
dae), and a collection of 1.6- to 1.8-kb dsRNA satellite
viruses termed M (M1, M2, M3, M28, . . .) (reviewed in
Wickner, 1996). The L-A ()-strand contains two open
reading frames: gag, which encodes its major coat pro-
tein; and pol, encoding a multifunctional protein domain
including the RNA-dependent RNA polymerase and do-
mains required for packaging of viral RNA. pol is only
translated as a Gag-pol fusion protein formed by a 1
ribosomal frameshift event. M1, the most well-character-
ized satellite virus of L-A, is encapsulated and replicated
inside of L-A encoded viral particles. Its translational
product is a secreted toxin that promotes killing of non-
virus-infected cells, while a killer toxin processing inter-
mediate confers immunity on infected cells. Cells har-
boring L-A and M1 have the Killer
 phenotype, which is
easily visualized by the halo of growth inhibition sur-
rounding colonies of infected cells. Since the underlying
“simultaneous slippage” mechanism of 1 PRF (Jacks et
al., 1988) is the same from L-A to HIV-1, the Killer virus
provides us with a simple, inexpensive model with which
to assay the genetic, biochemical, and pharmacological
parameters governing 1 PRF (reviewed in Dinman et
al., 1998).
Previous studies demonstrated that the most mean-
ingful ranges of drug concentrations to use in this type of
analysis were those at which cell growth was least
affected, and at which overall translation efficiencies
FIG. 1. Chemical structures of preussin and anisomycin.
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were inhibited by 50% (Dinman et al., 1997; Harger et
al., 2001). To determine a suitable range of concentra-
tions to analyze the effects of preussin on PRF, cell
growth was monitored by measuring the doubling times
of JD88 cells grown in selective medium at various drug
concentrations. We determined that cell growth was sig-
nificantly inhibited at concentrations  8 g/ml (data not
shown). To examine the relationship between preussin
concentrations and overall translation, -galactosidase
(-gal) activities were monitored in JD88 cells harboring
the p0 plasmid grown in the presence of different con-
centrations of preussin for 5 h. The results demonstrated
that at preussin concentrations between 5 and 6 g/ml,
overall translation in JD88 cells was inhibited by 50%
(see Fig. 2A). These results led us to conclude that 0–4
g/ml constituted an appropriate range of concentra-
tions over which to monitor the effects of preussin on
programmed ribosomal frameshifting. JD88 cells harbor-
ing the p0, p  1, or p  1 frameshift reporter plasmids
were grown in the presence of preussin at concentra-
tions of 1, 2, or 4 g/ml for 5 h, after which PRF efficien-
cies were determined as described under Materials and
Methods. These were compared to no-drug controls. The
results show that preussin specifically inhibited L-A vi-
rus-directed 1 PRF, whereas it had no effect on Ty1-
mediated 1 PRF (Figs. 2A, 2B, and Table 1). The effects
were specific to 1 PRF as evidenced by the enhanced
rate of decrease in -gal activities in cells harboring p 
1 as compared to either p0 or p  1 (Fig. 2A, Table 1).
Given the structural similarity between preussin and
anisomycin, we investigated whether the two com-
pounds were acting to inhibit programmed1 ribosomal
frameshifting through the same or different mechanisms.
Accordingly, cells were grown in the presence of one or
both agents for 5 h, after which1 PRF efficiencies were
determined. The results show that in the presence of
both compounds, inhibition of 1 PRF was intermediate
between anisomycin and preussin rather than additive
(Fig. 2C). The lack of an additive effect suggests that the
two drugs are acting through a similar mechanism or site
of action. The ability of preussin to partially block the
action of anisomycin supports this and suggests that it
has a higher affinity of their mutual target.
It is possible that increasing concentrations of aniso-
mycin or preussin preferentially destabilized the p  1
reporter mRNA, resulting in an apparent but not real
decrease in 1 PRF efficiency. To address this, RNase
protection assays were used to monitor the steady-state
abundances of the p0 and p  1 transcripts from cells
incubated with 0, 1, or 4 g/ml of preussin, and 0, 1, or 10
g/ml of anisomycin as described under Materials and
Methods. The results of this analysis are shown in Fig.
2D and quantitated in Table 2. Examination of Table 2
shows that the p  1 reporter mRNA was slightly stabi-
lized with respect to the 0-frame control reporter mRNA
in the presence of either of these compounds, suggest-
ing that the actual decreases in 1 PRF were even
greater than those calculated from the observed -gal
activities. These data demonstrate that the observed
dose-dependent decreases in 1 PRF in response to
these agents were not artifacts of changes in mRNA
stabilities.
Viral particle assembly and virus propagation are espe-
cially sensitive to decreases in PRF efficiencies (reviewed
in Dinman et al., 1998; also see Harger et al., 2001). To
examine the in vivo effects of preussin on virus propagation,
JD88 harboring L-A and M1 were cultured in the presence
of different concentrations of the compound and the effects
on the ability of cells to maintain both viruses over time
were assayed as described under Materials and Methods.
Similar to our observations with anisomycin, preussin was
also able to cure cells of the killer phenotype (Fig. 3A) in a
manner that correlated with increased time of incubation
with the compound (Fig. 3B). The observation that the rate
of loss of the killer phenotype is independent of the extent
of reduction in frameshifting efficiency suggests that elim-
ination of the preexisting intracellular pool of killer viruses
(estimated to be between 103 and 104 viral particles/cell,
see Wickner, 1996) is the rate-limiting parameter, in this
case as opposed to its being due to differences in the rates
of decrease of viral particle replacement consequent to
changes in frameshifting efficiencies. To determine the rea-
son for loss of the killer phenotype, total cellular RNA was
extracted, separated by electrophoresis, transferred to a
membrane, and hybridized with both L-A and M1 ()-
strand-specific probes, as described under Materials and
Methods. The results demonstrate that, although preussin
did not inhibit propagation of L-BC (Fig. 3C), a less well-
characterized endogenous yeast dsRNA virus (reviewed in
Wickner, 1996), neither the L-A nor the M1 dsRNA genomes
were present in cells grown in the presence of preussin
(Fig. 3D). Thus, loss of the killer phenotype was a conse-
quence of loss of both the L-A and the M1 viruses.
To summarize, examination of the literature for small
chemicals structurally similar to anisomycin led us to
preussin. Though it is also able to specifically inhibit 1
PRF, by itself preussin is probably not an ideal antiviral
compound. However, the work presented here is mean-
ingful with regard to drug discovery because it estab-
lishes that at least two pyrollidines have the ability to
inhibit programmed 1 ribosomal frameshifting and vi-
rus propagation. As such, it provides an opening to those
who are actively involved in drug discovery to look to-
ward new derivatives of pyrollidines as potential weap-
ons in the antiviral arsenal.
Ribosomal A-site-specific trans-acting factors: A
genetic analysis
By virtue of its ability to specifically inhibit accommo-
dation of the acceptor stem of aa-tRNAs into the ribo-
somal A-site, anisomycin, and by inference preussin, can
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be used as probes for ribosomal A-site specific func-
tions. Capitalizing on our large collections of mutants of
two A-site-specific trans-acting factors, eEF1A and eEF2,
we undertook a series of genetic analyses designed to
illuminate how the shared structural elements and ribo-
some binding properties of these two central translation
elongation factors influence their functional interactions
with the ribosomal A-site.
As a first step in this process, a series of strains
bearing mutations in subunits of eEF1 were assayed for
FIG. 2. Preussin specifically inhibits programmed 1 ribosomal frameshifting and cures yeast cells of the killer virus by the same mechanism as
anisomycin. (A) Effects of preussin on translation. Preussin was added to midlogarithmically growing JD88 cells harboring p0, p  1, or p  1 at the
indicated concentrations for 5 h after which -gal activities were determined as described under Materials and Methods. Those from cells exposed
to preussin were normalized to those obtained from no-drug controls. All assays were performed in triplicate. (B) Preussin specifically inhibits
programmed 1 ribosomal frameshifting. Preussin was added to midlogarithmically growing yeast cells at the indicated concentrations for 5 h after
which programmed 1 and 1 ribosomal frameshifting efficiencies were determined as described under Materials and Methods. All assays were
performed in triplicate. Error bars indicate % error. (C) Preussin and anisomycin act through the same mechanism or at the same site. Programmed
1 ribosomal frameshifting efficiencies were determined in midlogarithmically growing yeast cells after 5 h of growth in the presence of preussin
and/or anisomycin, as described above. Numbers indicate concentrations of the two compounds in g/ml. (D) Differences in PRF efficiencies are not
due to alterations in the steady-state abundances of the LacZ1 reporter mRNA. Cells harboring either p0 or p 1 were grown for 5 h in the absence
of either compound, 1 or 4 g/ml of preussin, or 2 or 10 g/ml of anisomycin, as indicated by ramps. Total cellular mRNA (20 g) was extracted and
subjected to RNase protection analysis using radiolabeled antisense probes corresponding to the 3 ends of the LacZ mRNA and U3 snRNA, as
previously described (Harger et al., 2001). The protected fragments are 200 and 85 nt, respectively, as indicated. Control lanes contained only tRNA
and either LacZ or U3 probes. Products were separated through a 6% PAGE urea denaturing gel and visualized using a Molecular Dynamics Typhoon
phosphorimager.
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altered resistance or sensitivity to preussin. Preliminary
studies to determine suitable drug concentrations
showed that the MC213/MC214 strain background was
slightly more sensitive to preussin than JD88. However,
the isogenic nature of the yeast strains derived from the
MC213/214 background allow for meaningful compari-
sons among those expressing wild-type and mutant
forms of eEF1 subunits. The effects of mutations (1) in
the GTP-binding domain of eEF1A (N153T, D156N,
N153TD156E, and E122K) (Carr-Schmid et al., 1999;
Dinman and Kinzy, 1997); (2) on both faces of the guanine
nucleotide exchange factor eukaryotic elongation factor
1B (eEF1B, formerly eEF1) (F163A and K120R-
S121L122) (Carr-Schmid et al., 1999; Andersen et al.,
2000); and (3) in cells lacking eEF1B and viable by
overexpression of eEF1A (Kinzy and Woolford, 1995)
were assayed for resistance to anisomycin and to preus-
sin. The results show that mutations in the “NKXD” GTP-
binding consensus element (i.e., N153T, D156N,
N153TD156E) resulted in increased resistance to
preussin, as evidenced by their increased viability in the
presence of 5 g/ml preussin, as compared to cells
expressing the wild-type form of eEF1A (Fig. 4A, com-
pare top row with the next three rows down). Conversely,
cells expressing the E122K mutation in eEF1A were
slightly more sensitive to preussin, showing decreased
viability in the presence of 5 g/ml preussin, as com-
pared to cells expressing the wild-type form of the pro-
tein (Fig. 4A, compare top and bottom rows). Interest-
ingly, this mutant was also hypersensitive to anisomycin
(Dinman and Kinzy, 1997), whereas this compound had
no discernible effect on cells harboring the NKXD alleles
(data not shown). We also observed that none of the
eEF1B mutants showed any effect, i.e., those affecting
its interaction with the G-domain of eEF1A (K120R-
S121L122), with domain II (F163A), and those entirely
lacking the eEF1B protein (data not shown). This is
consistent with our previous observations that alleles
eEF1B had no effects on programmed ribosomal frame-
shifting (Dinman and Kinzy, 1997).
We previously demonstrated that expression of the
E122K mutant form of eEF1A promoted elevated levels of
1 PRF and killer virus loss, but had no effect on1 PRF
(Dinman and Kinzy, 1997). Examination of PRF efficien-
cies in cells expressing the N153T, D156N, and
N153D156N mutants showed slight but repeatable re-
ductions in 1 PRF efficiencies, promoting 84% (N153T),
79% (D156N), and 66% (N153TD156E) of wild-type lev-
els, while no changes in 1 PRF were observed (data
not shown). Consistent with these observations, killer
assays showed that the halos of growth inhibition were
reduced in proportion to the extents of the 1 PRF
defects in isogenic strains expressing these mutant
forms of eEF1A (Fig. 4B). No effects on Ty1 retrotranspo-
sition frequencies were observed in any of the eEF1A
mutants (data not shown). This is consistent with the
TABLE 1
In vivo Effects of Preussin on Protein Synthesis
Preussin
-Gal activity
% 1 PRFb % 1 PRFcpOa p  1a p  1a
No-drug 87.50 7.94 1.71 0.14 5.16 0.23 1.95 0.12 5.9 0.27
(100) (100) (100) (100) (100)
1 g/ml 81.38 4.88 1.33 0.08 4.62 0.20 1.64 0.10 5.7 0.25
(0.93) (0.78) (0.90) (0.84) (0.97)
2 g/ml 73.50 5.14 1.09 0.06 4.26 0.27 1.49 0.09 5.8 0.23
(0.84) (0.64) (0.83) (0.76) (0.98)
4 g/ml 56.87 3.98 0.67 0.05 3.24 0.24 1.19 0.06 5.7 0.24
(0.65) (0.39) (0.63) (0.61) (0.97)
a -gal activities as a measure of the effects of preussin on translational competence. The -galactosidase values given here are as previously
defined (Dinman et al., 1991). The results normalized to “fold no-drug” controls are shown in parentheses.
b Percent programmed —1 ribosomal fameshifting was calculated by multiplying the ratio of p  1/p0 -gal activities by 100%. The results
normalized to “fold no-drug” controls are shown in parentheses.
c Precent programmed 1 ribosomal frameshifting was calculated by multiplying the ratio of p  1/p0 -gal activities by 100%. The results
normalized to “fold no-drug” controls are shown in parentheses.
TABLE 2
Quantitative Analysis of LacZ- and U3-Specific Bands
from Figure 2C
p0 p0 p  1 p  1
LacZ/U3
ratio
Fold 0
frame
LacZ/U3
ratio
Fold 0
frame
No drug 0.11 1 0.06 0.55
1 g/ml anisomysin 0.08 1 0.08 1.0
10 g/ml anisomysin 0.08 1 0.05 0.63
1 g/ml preussin 0.07 1 0.07 1.0
4 g/ml preussin 0.07 1 0.05 0.71
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integrated model of programmed ribosomal frameshift-
ing that predicts that alleles of TEF2 should affect either
1 PRF and killer virus maintenance or 1 PRF and Ty1
retrotransposition, but not both simultaneously (see Din-
man and Kinzy, 1997).
As demonstrated above, preussin resistance corre-
lated with decreased 1 PRF in cells expressing mutant
forms of eEF1A and vice versa. What does this tell us
about mechanism? Similar to N153 and D156, E122 is
located in the GTP-binding domain of eEF1A. However,
E122 lies in the fourth, nonconserved loop of this domain,
physically distinct from the other two amino acid resi-
dues alleles. The E122K allele is unique among the
original alleles isolated by Sandbaken and Culbertson
(1988) in its dramatic effect on 1 PRF and killer virus
maintenance (Dinman and Kinzy, 1997). One possible
model is that decreased GTP hydrolysis in this mutant
FIG. 4. Phenotypic analyses of yeast strains expressing mutant
forms of eEF1A and eEF2. (A) Strains expressing eEF1A with mutations
in the NKXD GTP-binding consensus element (D156N (TKY225), N153T
(TKY226), and N153TD156E (TKY229), another G-domain mutation of
E122K (TKY252), and wild-type eEF1A (MC214)) were assayed on plates
containing 5 g/ml preussin as described under Materials and Meth-
ods. Increased or decreased colony numbers at successive fivefold
dilutions are indicative of increased resistance or greater sensitivity to
preussin, respectively. (B) Killer virus phenotypes of strains expressing
wild-type eEF1A (MC213) or the mutants D156N (TKY278), N153T
(TKY280), N153T D156E (TKY282), or E122K (TKY113) were monitored
for viral maintenance by replica plating onto a lawn of 5x47-sensitive
cells as described under Materials and Methods. Decreases in the
diameter of the halos of growth inhibition are proportional to the extent
of changes in1 PRF efficiencies. (C) A subset of strains bearing eEF2
mutants (as described in Table 3) with IC50s  1.0 for preussin or
wild-type eEF2 were assayed on plates containing 250 ng/ml preussin
as described under Materials and Methods. The viability of cells in the
presence of 250 ng/ml of preussin is indicative of resistance to this
drug.
FIG. 3. Preussin promotes virus loss. JD88 cells were grown in rich
medium in the presence of the indicated concentrations of preussin for
1–5 days; aliquots of cells were removed at 1, 3, and 5 days, streaked
for single colonies onto rich medium lacking compounds, and repli-
cated to killer indicator plates. (A) Killer indicator plate. The presence
of the killer virus is indicated by the halo of growth inhibition around
Killer colonies. Loss of killer corresponds to the absence of the halo
of growth inhibition. (B) Rates of killer loss were calculated as de-
scribed under Materials and Methods. Preussin concentrations (g/ml)
are indicated. (C) Total nucleic acids were extracted from control
(Killer) and non-Killer colonies from the 5-day time point, separated by
agarose gel electrophoresis. The viral L-A, L-BC, and M1 dsRNAs are
indicated. (D) RNAs shown in C were transferred to nitrocellulose and
hybridized with L-A and M1 ()-strand probes and visualized by auto-
radiography as described under Materials and Methods.
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may slow down the accommodation step, increasing the
amount of time that ribosomes are paused the slippery
site, thus giving them more time to change frame. This
would account for the increased 1 PRF efficiencies
observed in cells expressing this form of the protein.
Furthermore, addition of agents that inhibit this step
would serve to exacerbate the intrinsic defect in the
ability of the E122K mutant to effect accommodation of
the aa-tRNA 3 end into the ribosomal A-site, accounting
for its hypersensitivity mutants to anisomycin and preus-
sin. Conversely, increased aa-tRNA accommodation
rates in the N153T, D156N, and N153D156N mutants,
e.g., through increased rates of intrinsic or facilitated
GTP hydrolysis, could account for both their decreased
rates of 1 PRF and their drug resistance. Though all of
these mutants show reduced fidelity, suggestive of al-
tered intrinsic GTPase activities, increased GTPase ac-
tivity has only been directly demonstrated for the N153T
mutant (Cavallius and Merrick JBC 1998). With regard to
1 PRF, increasing aa-tRNA accommodation rates
would decrease the amount of time that ribosomes
would be paused at the1 frameshift signal, decreasing
the likelihood of slippage. Furthermore, increasing the
intrinsic ability of eEF1A to accommodate the aa-tRNA
into the A-site of the peptidyl transferase center would
allow these forms of the protein to partially overcome the
blocks that anisomycin and preussin present at this step,
thus accounting for the relative drug resistance of cells
expressing the N153T, D156N, and N153D156N mu-
tants. While the link between reading frame maintenance
and preussin sensitivity correlates with virus loss, it is
also important to remember that several viruses recruit
eEF1A for functions including RNA binding such as in
West Nile virus and turnip yellow mosaic virus and as-
sociation with viral proteins such as vesicular stomatitis
virus RNA polymerase or HIV type I gag polyprotein
(reviewed in Kinzy and Goldman, 2000). Additional roles
for preussin on these functions remain to be determined.
The other elongation factor that interacts with the
ribosomal A-site is eEF2. Though mutants of eEF2 have
been shown not to affect 1 PRF efficiencies, since this
protein interacts with the same region of the ribosome as
eEF1A, it was reasonable to assume that preussin might
also alter its function as well. Our testing of this hypoth-
esis capitalized upon a series of isogenic strains EFT1
and EFT2 double-deletion strains harboring 14 different
plasmid-borne alleles of the EFT2 gene encoding eEF2
(Justice et al., 1998). While the YEFD12h strain back-
ground for the eEF2 mutants was intrinsically more sen-
sitive to preussin than the JD88 and MC213/214 back-
grounds, the isogenic nature of these strains allowed for
meaningful comparisons among cells expressing wild-
type and mutant forms of eEF2. Interestingly, the preus-
sin resistance profiles of these mutants closely paral-
leled those previously observed with the eEF2 inhibitor
sordarin (Justice et al., 1998) (Fig. 4C and Table 3). Sor-
darin allows eEF2 to bind ribosomes but inhibits GTP
hydrolysis by inhibiting the transition from the pre-trans-
located ribosomeeEF2GTP state to the post-translo-
cated ribosomeeEF2GTP state (Dominguez et al., 1999).
As discussed above, increased intrinsic GTP-hydrolysis
rates by the drug-resistant mutants is also consistent
with the observed correlation of preussin and sordarin
resistance and suggests that, similar to sordarin, preus-
sin may allow the elongation factors to bind to the ribo-
some, but inhibits their abilities to hydrolyze GTP.
To understand the relationship between the protein
structure and the drug-sensitivity phenotypes, the resi-
dues that affect preussin sensitivity were mapped onto
the structure of yeast eEF1A and a model of yeast eEF2
(Fig. 5). The mutations in eEF1A, shown on the yeast
eEF1A structure of domain 1 (Fig. 5A) (Andersen et al.,
2000), are distinct from the switch regions but are near
the nucleotide-binding site. For structure/function analy-
ses of eEF2, the homologous residues were mapped in
Thermus thermophilus EF-G (al Karadaghi et al., 1996;
Czworkowski et al., 1994) based on a gap alignment
using GCG, as the structure of eEF2 has not yet been
solved. Examination of the EF-G structure reveals that
the resistant mutations cluster predominantly around a
cleft in domain 3, including two residues in domain 5 that
contribute to this region (see Fig. 5B). In addition, two
separate mutations in domains 1 and one in domain 5
form a separate, distinct cluster on the exterior of the
protein. While some changes can be expected based on
the differences between EF-G and eEF2, these likely
serve as a starting point for identification of functional
regions. Since eEF1A and eEF2 both bind the A-site, but
at distinct steps in the elongation process, these results
may indicate regions that are more conserved in the
TABLE 3
Preussin IC50 of eEF2 Mutant Strains
Plasmida
Mutation in
eEF2a
IC50 (g/ml)
preussin
IC50 (g/ml)
sordarina
YCpEFT2 None 0.05 1
PSR13 R180G 0.66 15
PSR20 V187F 0.60 20
PSR8 Q490E 1.04 45
PSR16 Y521N 0.91 20
PSR27 S523F 1.06 100
PSR15 S523P 1.16 100
PSR6 I529T 0.88 30
PSR9 P559L 1.40 100
PSR11 P559R 1.16 100
PSR26 A562P 1.03 100
PSR12 P727S 1.60 100
PSR17 V774F 1.10 100
PSR7 G790D 2.0 100
a Plasmids, mutations in EFT2-encoded protein, preussin, and sor-
darin resistance in the YEFD12h strain background from (Justice et al.,
1998).
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FIG. 5. Mapping drug-resistant alleles onto the crystal structures of eEF1A and the eEF2 homolog EF-G. (A) Location of preussin-sensitive mutants
in the G-domain of yeast eEF1A (pdb entry 1F60). The residues N153 and D156 are marked with light spheres and E122 with a gray sphere. The thick
green loops contain the P-loop, the switch 1, and switch 2 region involved in binding of the phosphates of GDP or GTP and Mg2. The figure was
produced with MOLMOL (Koradi et al., 1996). (B) Location of residues (large spheres) in EF-G (pdb entry 1FNM) corresponding to the preussin-
sensitive mutants in eEF2 with amino acid residue numbers corresponding to eEF2 indicated. The structural domains in EF-G are shown in red, green,
blue, cyan, and gray for domains 1,2, 3, 4, and 5, respectively. Small magenta spheres in domain 1 represent bound GDP.
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nature of their interactions with the ribosome. Together,
the information on both proteins and their effects in the
presence of these compounds suggest new ways to
think about the control of gene expression and the ratio-
nal design of compounds that, by modulating it, possess
antiviral activities.
MATERIALS AND METHODS
Strains, genetic methods, drugs, and media
Escherichia coli strains DH5 and MV1190 were used
to amplify plasmids, and E. coli transformations were
performed using standard calcium chloride method as
described previously (Sambrook et al., 1989). Preussin
was purified as previously described (Schwartz et al.,
1988), and anisomycin was obtained from Sigma Chem-
ical Corp. (St. Louis, MO). All eEF2 mutant strains were
prepared by transformation of the indicated plasmid in
Table 3 into YEPD12h followed by growth on 5-fluoro-
orotic acid. Yeast strains are given in Table 4 and were
transformed using the alkali cation method (Ito et al.,
1983). YPAD, YPG, SD, synthetic complete medium (H),
and 4.7-MB plates for testing the killer phenotype were
used as described previously (Wickner and Leibowitz,
1976). Cytoduction of L-A and M1 from kar1-1 donor
strains into rho-0 acceptor strains were as previously
described (Dinman and Wickner, 1994). Determination of
IC50 values for preussin for the eEF2 mutants were as
previously described (Justice et al., 1998). Plate assays
for preussin and anisomycin sensitivity/resistance were
performed by growing the indicated strains overnight in
YPAD at 29°C. Cells were diluted to A600 of 0.05 and
serial fivefold dilutions (4 l) were spotted onto YPAD
plates containing preussin at 5 g/ml for the eEF1 mu-
tant strains and 250 ng/ml for the eEF2 mutant strains.
The plates were incubated at 29°C for 5–7 days.
Programmed ribosomal frameshift and RNase
protection assays
The plasmids p0, p  1, and 1 used to monitor PRF
have been described previously (Harger et al., 2001). In
these plasmids, transcription is driven from the yeast
PGK1 promoter; the enzymatic reporter is composed of
the E. coli lacZ gene, and transcription termination uti-
lizes the yeast PGK1 transcriptional terminator. In the p0
plasmids, lacZ is in the 0-frame with respect to the
translational start site, and measurement of -gal activity
generated from cells transformed with these plasmids
serve as the 0-frame controls. In the p  1 series, lacZ is
in the1 frame with respect to the translational start site
TABLE 4
S. cerevisiae Strains Used in This Study
Strain Genotype Source
5x47 MATa/MAT his1/ trp1/ ura3/ K-R- (Dinman and Kinzy, 1997)
JD88 MATa ura3-52 lys2-801 ade2-10 trp1-1 [L-AHNB M1] Dinman Lab
MC213 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1 pTEF2-URA3 (Sandbaken and Culbertson, 1988)
MC214 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1 pTEF2-TRP1 (Sandbaken and Culbertson, 1988
TKY113 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1
pTEF2-4-URA3 (E122K)
(Dinman and Kinzy, 1997)
TKY225 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1
ptef2-17-TRP1 (D156N)
(Carr-Schmid et al., 1999)
TKY226 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1
ptef2-19-TRP1 (N153T)
(Carr-Schmid et al., 1999
TKY229 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1 ptef2-18-TRP1
(N153T/D156E)
(Carr-Schmid et al., 1999
TKY235 MAT ura3-52 leu21 met2-1 trp1101 his4-713 lys2-801 met2-1 tef5:::TRP1 pTEF5 LEU2 (Carr-Schmid et al., 1999)
TKY243 MAT ura3-52 leu21 met2-1 trp1101 his4-713 lys2-801 met2-1 tef5::TRP1 ptef5-7 LEU2
(K120RS121I122)
(Carr-Schmid et al., 1999
TKY252 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1
pTEF2-4-TRP1 (E122K)
This study
TKY278 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1
ptef2-17-URA3 (D156N)
(Carr-Schmid et al., 1999)
TKY280 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1
ptef2-19-URA3 (N153T)
(Carr-Schmid et al., 1999
TKY282 MAT ura3-52 leu2-3, 112 his4-713 trp11 tef2 tef1::LEU2 lys2-20 met2-1 ptef2-18-URA3
(N153T  D156E)
(Carr-Schmid et al., 1999
TKY298 MAT ura3-52 leu21 met2-1 trp1101 his4-713 lys2-801 met2-1 tef5::TRP1 pTEF2 URA3 (Andersen et al., 2001)
TKY370 MAT ura3-52 leu21 met2-1 trp1101 his4-713 lys2-801 met2-1 tef5::TRP1
ptef5-23 LEU2 (F163A)
(Andersen et al., 2000)
TKY128 MAT alpha ade2 lys2 leu2 his3 trp1 ura3 eft1::HIS3 eft2::TRP1 pEFT2-LEU2 (Justice et al., 1998)
YEFD12h MATa ade2 ura3 his3 leu2 trp1 eft1::HIS3 eft2::TRP1  YCpEFT2 (Justice et al., 1998
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and is 3 of the L-A 1 PRF signal such that -gal can
only be produced as a consequence of a 1 PRF event.
Similarly, in the p 1 series, lacZ is in the1 frame with
respect to the translational start site and is 3 of the Ty1
1 PRF signal. The efficiency of programmed ribosomal
frameshifting is calculated by determining the ratio of
-gal activity produced by cells harboring either p  1 or
p  1 divided by the -gal activity produced by cells
harboring p0 and multiplying by 100%. All assays were
performed in triplicate on three different occasions. Mea-
surements of the effects of preussin and anisomycin on
programmed ribosomal frameshifting were performed as
described previously (Dinman et al., 1997). Briefly, 0.5 ml
of overnight cultures of JD88 cells were diluted into 2 ml
of fresh medium containing either of the two compounds,
or drug-free controls (starting O.D.595  0.3–0.5). The final
concentrations of anisomycin were 2, 4, or 10 g/ml, and
the final concentrations of preussin were 1, 2, or 4 g/ml.
Cultures were incubated at 30°C for 5 h, after which
frameshifting efficiencies were determined as described
above. RNase protection assays were performed as pre-
viously described probing for LacZ mRNA steady-state
abundances, which were normalized to U3 snRNA
(Harger et al., 2001).
Virus propagation assays
The killer assay was done by replica-plating Saccha-
romyces cerevisiae colonies onto 4.7-MB plates (Wick-
ner and Leibowitz, 1976) with a freshly seeded lawn of
strain 5x47 (0.5 ml of a suspension at 1 unit of optical
density at 550 nm per ml per plate). After 2–3 days at
20°C, killer activity was observed as a zone of growth
inhibition around the killer colonies. dsRNA of L-A and
M1 viruses were prepared as described (Liermann et al.,
2000), separated by electrophoresis through 1.0% aga-
rose gels, and visualized by ethidium bromide staining.
The abundance of L-A and M1 dsRNAs were monitored
by RNA blotting as previously described (Dinman and
Wickner, 1994). Rates of loss of killer virus were moni-
tored as previously described (Dinman et al., 1997).
Briefly, cells were grown in rich medium containing the
same concentrations of preussin as described above
and were passaged into fresh compound-containing me-
dium every 24 h. Aliquots of cells were taken after 1, 3,
and 5 days and plated onto rich media to allow growth of
single colonies for 2–3 days, after which they were as-
sayed for killer activity. The frequency of killer loss was
measured by the ratio of Killer-/total colonies. A minimum
of 100 individual colonies were assayed for each com-
pound concentration and each time point. Assays to
monitor Ty1 retrotransposition frequencies were per-
formed as previously described (Harger et al., 2001).
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